Nervous tissue is more susceptible to oxidative damage than other tissue, because it has a high content of unsaturated fatty acids. Moreover, the brain has high metabolic activity and relatively low antioxidant defense \[[@B1]\]. In aging progresses, oxidative damage accumulates and the brain undergoes morphologic and functional changes \[[@B2]\]. Finally oxidative damage causes chronic inflammation in the aged brain. Neuroinflammation induces the activation of microglia in the brain and active microglia secrete pro-inflammatory cytokines (M1 microglia) or have important roles in brain repair and plasticity (M2 microglia) \[[@B3]\]. Activated microglia release neurotoxic substances and pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) \[[@B4][@B5][@B6]\]. In contrast, anti-inflammatory cytokines such as IL-4 and IL-10 may decrease neuroinflammation by regulating the production of IL-1β or IL-6 \[[@B7]\].

There are several animal models for the study of aging. However, the [D]{.smallcaps}-galactose model is the most convenient and can be compared to natural aging studies. Under normal condition, diet-fed [D]{.smallcaps}-galactose can be metabolized by two enzymes in the body: [D]{.smallcaps}-galactokinase and galactose-1-phosphate uridyl transferase. However, repeated treatment of [D]{.smallcaps}-galactose can be converted into hydrogen peroxide in the presence of galactose oxidase, leading to the formation of a superoxide anion \[[@B8]\]. Administration of [D]{.smallcaps}-galactose shows aging phenotypes such as impairment of spatial learning and memory, and neurodegeneration and neuroinflammation \[[@B8]\].

*Dendropanax morbifera* Léveille (*D. morbifera*) is an endemic species distributed in the southwest costal region and Jeju island of South Korea. Several lines of evidence demonstrate that *D. morbifera* leaf extract (DML) has antioxidant \[[@B9][@B10][@B11]\] and anti-inflammatory \[[@B12][@B13]\] effects. In particular, in our previous study, we demonstrated that *D. morbifera* stem extract ameliorates streptozotocin-induced memory impairment, microglial activation, and release of TNF-α and IL-1β in the hippocampus \[[@B13]\].

However, there are few reports on the effects of DML on age-related changes of hippocampal function. Therefore, in the present study, we evaluated the effects of DML on hippocampal function using a Morris water maze task, and microglial activation and subsequent cytokine release using immunohistochemistry and enzyme-linked immunosorbent assay (ELISA), respectively, in [D]{.smallcaps}-galactose treatment-induced aged mouse hippocampus.

Materials and Methods
=====================

Experimental animals
--------------------

Male C57BL/6 mice were purchased from Orient Bio Inc. (Seongnam, South Korea). Rats were housed in a conventional animal facility at 23℃ with 60% humidity, a 12-h/12-h light/dark cycle, and free access to food and tap water. The handling and care of the animals conformed to the guidelines established to comply with current international laws and policies (NIH Guide for the Care and Use of Laboratory Animals, NIH Publication No. 85-23, 1985, revised 1996). Ethical and experimental protocol approvals were obtained from the Institutional Animal Care and Use Committee (IACUC) of Kangwon National University (KW-161014-1). All of the experiments were conducted with an effort to minimize the number of animals used and the suffering caused by the procedures employed.

Preparation of DML
------------------

Fresh *D. morbifera* was supplied by HBJ Biofarm (Jeju, South Korea). The plant was identified by two practitioners of traditional Asian medicine. Leaves from the plant samples (100 g) were chopped, blended, soaked in 2 L of 80% ethanol, and then refluxed three times at 20℃ for 2 h. Insoluble materials were removed by centrifugation at 10,000×*g* for 30 min, and the resulting supernatant was concentrated and freeze-dried to yield a powder. Before each experiment, dried extracts were dissolved in distilled and deionized water.

Administration of [D]{.smallcaps}-galactose and (DML)
-----------------------------------------------------

Animals were divided into 3 groups (*n*=10 in each group): vehicle-treated, [D]{.smallcaps}-galactose-treated, and [D]{.smallcaps}-galactose with DML treated group. D-Galactose (100 mg/kg) and DML (100 mg/kg) were subcutaneously and orally administered to 7-week-old mice once a day for 10 weeks.

Water maze performance
----------------------

During the 10th week after [D]{.smallcaps}-galactose administration, spatial memory was assessed using a Morris water maze as described previously \[[@B14]\]. Morris water maze tests were performed in order to ensure objectivity in blind conditions. Three days after the training, the time individual mice spent to find the submerged platform (within 2 min) (escape latency) and the swimming distance were monitored by a digital camera and a computer system for 4 consecutive days during 4 trials per day. The administration of [D]{.smallcaps}-galactose and DML was continued during the water maze performance. For each trial, a mouse was placed in the water facing the wall at one of four starting positions and released. The swimming speed and the time required for the mouse to find the hidden platform were recorded via visual tracking system. The probe test was done on day 5; the platform was removed and the time that the mouse spent swimming in the target quadrant and in the three non-target quadrants (right, left, and opposite quadrants) was measured in the training and opposite quadrants for 60 s. In addition, the number of times the mouse crossed the platform site was recorded.

Tissue processing
-----------------

For immunohistochemical analysis, vehicle-treated, [D]{.smallcaps}-galactose-treated, and [D]{.smallcaps}-galactose with DML treated mice (*n*=5 per group) were anesthetized with 1 g/kg urethane (Sigma-Aldrich, St. Louis, MO, USA) and perfused with 0.1 M phosphate-buffered saline (PBS, pH 7.4) followed by 4% paraformaldehyde in 0.1M phosphate-buffer, pH 7.4. Brains were removed and postfixed in the same fixative for 24 h. Subsequently, the brain was dehydrated with graded concentrations of alcohol before being embedded in paraffin. Paraffin-embedded tissues were sectioned into 3-µm coronal sections using a microtome (Leica Microsystems GmbH, Wetzlar, Germany) and were mounted onto silane-coated slides (Muto Pure Chemicals Co., Ltd, Tokyo, Japan).

Immunohistochemistry for Iba-1
------------------------------

To ensure that the immunohistochemical data was comparable among groups, sections were carefully processed under the same conditions. Sections were hydrated and treated with 0.3% hydrogen peroxide (H~2~O~2~) in phosphate-buffered saline (PBS) for 30 min. For antigen retrieval, the sections were placed in 400-mL jars filled with citrate buffer (pH 6.0) and heated in a 2100-retriever (Prestige Medical, Lancashire, UK). After antigen retrieval, slides were allowed to cool at room temperature and were washed in PBS. After washing, sections were incubated in 10% normal goat serum in PBS for 30 min. Sections were then incubated with rabbit anti-Iba-1 antibody (1:500, Wako, Osaka, Japan) for 48 h at 4℃. Sections were subsequently exposed to biotinylated goat anti-rabbit IgG, or anti-mouse IgG (diluted 1:200, Vector Laboratories, Inc., Burlingame, CA, USA), and streptavidin peroxidase complex (diluted 1:200, Vector Laboratories). Finally, sections were stained with 3,3-diaminobenzidine tetrahydrochloride (Sigma, St. Louis, MO, USA) in 0.1 M Tris-HCl buffer (pH 7.4).

Analysis of the regions of interest in the hippocampal CA1 region was performed using an image analysis system. Images were calibrated into an array of 512×512 pixels corresponding to a tissue area of 140 µm×140 µm (40× primary magnification). Pixel resolution was 256 gray levels. The intensity of Iba-1 immunoreactivity was evaluated by relative optical density (ROD), which was obtained after transformation of the mean gray level using the formula: ROD=log(256/mean gray level). The ROD of the background was determined in unlabeled portions (white matter region) and this value was subtracted to normalize the corrected optical densities using ImageJ 1.50 software (National Institutes of Health, Bethesda, MD, USA). The ratio of the ROD was calculated as percentage relative to control (vehicle-treated group).

ELISA for cytokines
-------------------

To measure changes in TNF-α, IL-1β, IL-4, IL-6, and IL-10 levels in the hippocampus, vehicle-treated, [D]{.smallcaps}-galactose-treated, and [D]{.smallcaps}-galactose with DML treated mice (*n*=5) were sacrificed and used for ELISA. After sacrificing the mice and removing the hippocampus, hippocampal tissues were homogenized in ice-cold 50 mM sodium phosphate buffer (pH 7.4) containing 0.1 mM ethylenediaminetetraacetic acid (EDTA) by using a glass-teflon homogenizer (Heidolph Silent Crusher M, Germany). The supernatant was separated by centrifugation at 20,000×*g* for 20min at 4℃. TNF-α, IL-1β, IL-4, IL-6, and IL-10 were measured in the supernatant of homogenized hippocampal tissue by using ELISA kits (EMD Millipore, Billerica, MA, USA). The procedures were carried out according to the manufacturer\'s instructions. TNF-α, IL-1β, IL-4, IL-6, and IL-10 levels were determined from a standard curve and were expressed in pg/mg protein.

Statistical analysis
--------------------

Data are expressed as means for each experiment. The differences among the means were statistically analyzed by one- or two-way analysis of variance (ANOVA) with repeated measures and Bonferroni\'s post hoc test using GraphPad Prism 5.01 software (GraphPad Software, Inc., La Jolla, CA). Threshold for statistical significance was set to *P*\<0.05.

Results
=======

Effects of [D]{.smallcaps}-galactose and/or DML on spatial memory in mice
-------------------------------------------------------------------------

Mean escape latency in the [D]{.smallcaps}-galactose-treated group was longer than in the vehicle-treated group on all days of experiments. However, differences were only significant on days 2, 3, and 4. Administration of DML to the [D]{.smallcaps}-galactose-treated group resulted in shorter mean escape latencies compared to escape latencies in the [D]{.smallcaps}-galactose-treated group. Differences were statistically significant on days 2 and 4. There was no significant difference in escape latency between the vehicle-treated group and [D]{.smallcaps}-galactose-treated group with DML ([Figure 1A](#F1){ref-type="fig"}).

Mean swimming speed tended to be decreased after successive trials. In addition, mean swimming speed was slower in the [D]{.smallcaps}-galactose-treated group than in the vehicle-treated group. Administration of DML to the [D]{.smallcaps}-galactose-treated group increased the swimming speed in all trials although this tendency was not statistical significant ([Figure 1B](#F1){ref-type="fig"}).

Significantly fewer platform crossings in the probe trial were observed in the [D]{.smallcaps}-galactose-treated group compared to the vehicle-treated group. Administration of DML to the [D]{.smallcaps}-galactose-treated group significantly increased the frequency of crossing over the platform site relative to that in the [D]{.smallcaps}-galactose-treated group and similar to that in the vehicle-treated group ([Figure 1C](#F1){ref-type="fig"}).

In the probe trial for the escape latency task, mice form the [D]{.smallcaps}-galactose-treated group took significantly longer to find the target platform location than mice from the vehicle-treated group. Administration of DML to the [D]{.smallcaps}-galactose-treated group significantly reduced the time mice required to find the target platform ([Figure 1D](#F1){ref-type="fig"}).

Effects of [D]{.smallcaps}-galactose and/or DML on the morphology of Iba-1-immunoreactive microglia
---------------------------------------------------------------------------------------------------

In the vehicle-treated group, Iba-1-immunoreactive microglia were present throughout hippocampus. These microglia showed small cytoplasms and long processes ([Figure 2A](#F2){ref-type="fig"}). In the [D]{.smallcaps}-galactose-treated group, the distribution pattern was similar to that in the vehicle-treated group. However, Iba-1 immunoreactive microglia showed hypertrophy of the cytoplasm with highly ramified processes ([Figure 2B](#F2){ref-type="fig"}). In this group, Iba-1 immunoreactivity was significantly increased by 148.6% relative to the vehicle-treated group ([Figure 2D](#F2){ref-type="fig"}). In the [D]{.smallcaps}-galactose-treated group with DML, only a few Iba-1 immunoreactive microglia had hypertrophied cytoplasm, while most cells had small cytoplasms ([Figure 2C](#F2){ref-type="fig"}). In addition, Iba-1 immunoreactivity was significantly decreased in this group compared to that in the [D]{.smallcaps}-galactose-treated group ([Figure 2D](#F2){ref-type="fig"}).

Effects of [D]{.smallcaps}-galactose and/or DML on pro- and anti-inflammatory cytokines
---------------------------------------------------------------------------------------

In the [D]{.smallcaps}-galactose-treated group, pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 significantly increased by 1.71--2.46 fold relative to the vehicle-treated group in hippocampal homogenates. Anti-inflammatory cytokine IL-4 was significantly decreased in the [D]{.smallcaps}-galactose-treated group by 59.7% relative to the vehicle-treated group. In contrast, administration of DML to the [D]{.smallcaps}-galactose-treated group significantly decreased TNF-α, IL-1β, and IL-6 levels and increased IL-4 levels in hippocampal homogenates. However, IL-10 level did not change significantly among the hippocampal homogenates of the different groups ([Figure 3](#F3){ref-type="fig"}).

Discussion
==========

Mounting evidence suggests that, with advancing age, the brain atrophies and its capacity for plasticity decreases \[[@B15]\]. In addition, age-related deficits resemble the deficits observed following bilateral damage to the hippocampus \[[@B16]\]. In the present study, we investigated the effect of DML on [D]{.smallcaps}-galactose-induced impairment of hippocampal functions based on the Morris water maze task. The Morris water maze task has been generally accepted as the key method for studying the relationship between hippocampal function and spatial learning and memory in rodents \[[@B17]\]. Repeated exposure to [D]{.smallcaps}-galactose for 10 weeks significantly decreased the spatial learning ability of mice. Supplementation of [D]{.smallcaps}-galactose with DML ameliorated reduced spatial learning ability. This result is consistent with results from a previous study showing that long-term treatment with [D]{.smallcaps}-galactose induces learning and memory deficits in both water maze and step-down latency \[[@B18]\]. In addition, *D. morbifera* stem extracts significantly improved novel object recognition memory in cadmium-exposed rats \[[@B19]\]. In addition, ethyl acetate fraction of *D. morbifera* ameliorated high fat diet-induced memory impairment measured in Y-maze, passive avoidance, and Morris water maze tests \[[@B20]\].

Aging is closely related to microglial activation. We monitored the effects of DML on [D]{.smallcaps}-galactose-induced morphological changes in Iba-1-immunoreactive microglia. Administration of [D]{.smallcaps}-galactose for 10 weeks induced microglial activation indicated by morphological changes from small cytoplasm with thin and long processes to hypertrophied cytoplasm and processes. A flow cytometry study previously demonstrated that activated microglia labeled with CD86 and MHC II are more common in aged (22-month-old) mice than in young adult (4-month-old) mice \[[@B21]\]. In the present study, administration of DML to [D]{.smallcaps}-galactose-exposed mice significantly decreased microglia activation. This result is in line with a previous study showing that *D. morbifera* stem extract significantly reduces the morphological changes indicative of the activated form of microglia in streptozotocin-exposed hippocampi \[[@B13]\].

In the present study, we analyzed the pro- and anti-inflammatory cytokines because microglial activation is associated with cytotoxicity \[[@B4][@B7]\] and neuroprotection \[[@B22]\]. Exposure to [D]{.smallcaps}-galactose for 10 weeks significantly increased the levels of TNF-α, IL-1β, and IL-6 in hippocampal homogenates. An *in vitro* neuron-microglia co-culture study showed that activated microglia elevate TNF-α and IL-1β mRNA \[[@B23]\]. IL-1β, IL-6, and TNF-α are released in the Alzheimer brain during chronic inflammation \[[@B24]\]. In addition, IL-6 levels are higher in the hippocampus of aged mice than in juvenile and adult mice \[[@B25]\]. In the present study, the administration of DML to [D]{.smallcaps}-galactose-treated mice significantly reduced [D]{.smallcaps}-galactose-induced increases of TNF-α, IL-1β, and IL-6. These results suggest that DML reduces neuroinflammation in the hippocampus of [D]{.smallcaps}-galactose-exposed mice. This finding may be closely related to the age-related impairment of memory function, because increases of IL-1β or IL-6 have been shown to correlate with the tau-phosphorylation in the Alzheimer brain \[[@B26]\]. In addition, elevated IL-1β decreases long-term potentiation (LTP) sustainability \[[@B27]\]. Conversely, lowering hippocampal IL-1β using minocycline treatment partially rescues this impairment in LTP \[[@B28]\]. In addition, *D. morbifera* stem extract also alleviates streptozotocin-induced increases in TNF-α and IL-1β levels in hippocampal homogenates \[[@B13]\].

In the present study, we observed that exposure to [D]{.smallcaps}-galactose significantly decreases IL-4 levels, and slightly increases IL-10 levels in hippocampal homogenates of mice. Furthermore, we observed that administration of DML to [D]{.smallcaps}-galactose-exposed mice rescued of IL-4 levels in the hippocampal homogenates. This result suggests that DML significantly increases the anti-inflammatory cytokine IL-4, but not IL-10, to reduce the inflammatory responses in the hippocampus. IL-4 levels have been shown to be increased in aged brains with increased neuroinflammation and reduced LTP \[[@B29]\]. Induction of hippocampal IL-4 restored LTP in the aged rats \[[@B30]\] and in the adult brains exposed to amyloid-β protein \[[@B31]\]. However, there have been conflicting reports on age-related changes of IL-10 levels in the brain. Ye and Johnson \[[@B32]\] demonstrated that IL-10 levels are decreased in aged (24-month-old) mouse brains. This may contribute to the increased expression of IL-6 in aged mouse brains. In contrast, Petez et al \[[@B33]\] observed slightly increased IL-10 expression in the aged (18-month-old) hippocampus relative to the adult (4-month-old) hippocampus in C57BL/6 mice. Other groups have also demonstrated that activated microglia from aged mice showed higher levels of IL-10 than activated microglia from adult mice \[[@B34]\]. In the present study, we did not observe any significant changes in IL-10 levels in hippocampal homogenates of [D]{.smallcaps}-galactose-treated mice. The discrepancies may be associated with the analysis methods used to measure IL-10 levels.

In conclusion, DML significantly ameliorates signs of [D]{.smallcaps}-galactose-induced mouse senescence by decreasing pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6, and increasing anti-inflammatory cytokine IL-4 in hippocampus.
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